Back to Search Start Over

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Authors :
Migliori GB
Sotgiu G
Rosales-Klintz S
Centis R
D'Ambrosio L
Abubakar I
Bothamley G
Caminero JA
Cirillo DM
Dara M
de Vries G
Aliberti S
Dinh-Xuan AT
Duarte R
Midulla F
Solovic I
Subotic DR
Amicosante M
Correia AM
Cirule A
Gualano G
Kunst H
Palmieri F
Riekstina V
Tiberi S
Verduin R
van der Werf MJ
Source :
The European respiratory journal [Eur Respir J] 2018 May 17; Vol. 51 (5). Date of Electronic Publication: 2018 May 17 (Print Publication: 2018).
Publication Year :
2018

Abstract

The International Standards for Tuberculosis Care define the essential level of care for managing patients who have or are presumed to have tuberculosis, or are at increased risk of developing the disease. The resources and capacity in the European Union (EU) and the European Economic Area permit higher standards of care to secure quality and timely TB diagnosis, prevention and treatment. On this basis, the European Union Standards for Tuberculosis Care (ESTC) were published in 2012 as standards specifically tailored to the EU setting. Since the publication of the ESTC, new scientific evidence has become available and, therefore, the standards were reviewed and updated.A panel of international experts, led by a writing group from the European Respiratory Society (ERS) and the European Centre for Disease Prevention and Control (ECDC), updated the ESTC on the basis of new published evidence. The underlying principles of these patient-centred standards remain unchanged. The second edition of the ESTC includes 21 standards in the areas of diagnosis, treatment, HIV and comorbidities, and public health and prevention.The ESTC target clinicians and public health workers, provide an easy-to-use resource and act as a guide through all the required activities to ensure optimal diagnosis, treatment and prevention of TB.<br />Competing Interests: Conflict of interest: S. Aliberti reports grants and personal fees from Bayer Healthcare, Aradigm Corporation, Grifols, Chiesi and INSMED, and personal fees from AstraZeneca, Basilea, Zambon, Novartis, Raptor, Actavis UK Ltd and Horizon, outside the submitted work.<br /> (The content of this work is copyright of the authors or their employers. Design and branding are copyright ©ERS 2018.)

Details

Language :
English
ISSN :
1399-3003
Volume :
51
Issue :
5
Database :
MEDLINE
Journal :
The European respiratory journal
Publication Type :
Academic Journal
Accession number :
29678945
Full Text :
https://doi.org/10.1183/13993003.02678-2017